Future research directions for ER+ positive breast cancer

Hiroji Iwata, MD, PhD, Aichi Cancer Center Hospital, Nagoya, Japan, discusses the future of research into estrogen receptor-positive (ER+) HER2-negative breast cancer, including investigation into which patients are good candidates for adjuvant endocrine therapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.